Discontinued — last reported Q4 '25
Erleada — Milestone payable
Royalty Pharma Erleada — Milestone payable decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $12.40M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates the successful achievement of a clinical or commercial milestone, which typically validates the asset's progress but results in a short-term cash outflow. A decrease suggests no major milestones were met during the period, potentially indicating a slower pace of development or market penetration.
Detailed definition
This metric represents the contingent payments owed to third-party licensors or partners triggered by the achievement of...
Peer comparison
Similar to contingent consideration or milestone payments found in pharmaceutical licensing agreements, where payments are tied to regulatory approvals or sales volume targets.
rprx_segment_erleada_milestone_payableHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|---|---|
| Value | $3.10M | $3.10M | $3.10M | $3.10M | $0.00 | $12.40M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% | — | -100.0% |
| YoY Change | — | — | — | — | -100.0% | — | -100.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's erleada — milestone payable?
- Royalty Pharma (RPRX) reported erleada — milestone payable of $0.00 in Q4 2025.
- How has Royalty Pharma's erleada — milestone payable changed year-over-year?
- Royalty Pharma's erleada — milestone payable decreased by 100.0% year-over-year, from $12.40M to $0.00.
- What does erleada — milestone payable mean?
- The amount of one-time payments due to partners when a specific product reaches pre-agreed development or sales goals.